Skip to content

Offering Cervical Cancer Screening to Older Women

Reducing the Burden of Cervical Cancer Among Older Women by Expanding the Screening Age and Offering HPV Self-sampling

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04114968
Enrollment
20000
Registered
2019-10-03
Start date
2019-09-30
Completion date
2025-12-31
Last updated
2020-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mass Screening, Uterine Cervical Disease, Uterine Cervical Neoplasm, Uterine Neoplasm

Keywords

HPV self-sampling, cervical cancer screening in older women

Brief summary

This study evaluates the effect and feasibility of expanding the target population in the Danish cervical cancer screening program to include women aged 65 to 69 years. The study also evaluates if HPV self-sampling constitutes an appropriate screening method among older women.

Detailed description

The study is a nationwide population-based prospective cohort study embedded in the routine cervical cancer screening program in the Central Denmark Region. The study includes all 65 to 69 years old Danish women with no record of a cervical cytology sample or screening invitation within the last five years. Furthermore, the women are not registered as ineligible for screening, eg due hysterectomy. Eligible women residing in the Central Denmark Region are allocated to the intervention group (n=20,000), while women residing in the other four Danish regions are allocated to the control group receiving standard care (n=71,500), which for this group is low-level opportunistic screening at the general practitioner (GP). The intervention group are invited for HPV-based screening by the GP or to request a self-sampling kit.

Interventions

OTHERGP-based screening or HPV self-sampling

Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
65 Years to 69 Years

Inclusion criteria

* 65 to 69 years; * Resident in Denmark * No record of a cervical cytology or screening invitation in the past 5 years * Not registered as ineligible for screening

Exclusion criteria

* Death * Migration to or from Denmark * Moving to or from the CDR * Residing in the CDR, but having GP in another region * A record of hysterectomy

Design outcomes

Primary

MeasureTime frameDescription
HPV prevalence1 year post invitationNumber of women tested positive for HPV
Participation rate in the intervention group:1 year post invitationParticipation rate, eg the roportion of targeted women participating by GP-based screening or self-sampling
Compliance to follow-up among HPV-positive self-samplers90 days post test resultsThe proportion of HPV-positive self-samplers who attend appropriate follow-up by their GP for onward referral
Screening historyAverage of 10 yearsScreening history of participants and non-participants in the intervention group
Intervention versus control group:1 year post invitationParticipation rate
Cytological findings1 year post invitationProportion of abnormal cytological findings between the intervention and control group is compared
Histological findings1 year post invitationProportion of abnormal histological findings between the intervention and control group is compared
Incidence5 year post invitationThe incidence rate of cervical cancer developed within 5 year is compared between the intervention and control group
Mortality5 year post invitationThe mortality rate of cervical cancer developed within 5 year is compared between the intervention and control group

Countries

Denmark

Contacts

Primary ContactMette Tranberg, Post doc PhD
mettrani@rm.dk+45 784 20264

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026